Therapeutic area · RespiratoryUpdated September 28, 2026

EDC for COPD and asthma trials, built around exacerbations

Respiratory trials count exacerbations over a year, measure lung function at visits and ask participants about symptoms and rescue inhaler use every day. Capture puts the exacerbation forms, daily diaries and questionnaires in one study with one audit trail.

  • Exacerbation forms
  • Daily rescue medication diary
  • CAT, ACT and other PROs

Free sandbox · No credit card · 21 CFR Part 11 aligned

Exacerbation · Unscheduled
Subject 008-0031 · Reported at Week 19Submitted

Onset date

EXSTDTC
14-Feb-2027

Systemic corticosteroids given

EXSCS
NoYes

Antibiotics given

EXABX
NoYes

Emergency visit or hospital admission

EXHOSP
NoYes

Resolution date

EXENDTC
02-Mar-2027
Severity classified from treatment and setting

What matters in COPD and asthma trials

  • The annualised rate of moderate or severe exacerbations is the primary endpoint in many COPD and severe asthma trials. Moderate events are typically defined by treatment with systemic corticosteroids or antibiotics; severe events by hospital admission or emergency care.
  • Lung function, usually FEV1 by spirometry, is the key endpoint for bronchodilators and a common secondary elsewhere. Spirometry should follow ATS/ERS standards, often with central over-reading.
  • Daily eDiaries record symptoms, night-time waking and rescue inhaler use, and can help detect exacerbations early.
  • Patient-reported outcomes include the CAT and SGRQ in COPD, and the ACT or ACQ in asthma.
  • Exacerbations are seasonal, so many trials run for 52 weeks to cover a full year.

Study design

Counting exacerbations reliably

An exacerbation endpoint is only as good as the capture of events between visits. Participants may be treated by their own doctor, an urgent care clinic or an emergency department, and the site learns about it weeks later. Trials handle this by asking about exacerbations at every contact, prompting participants to report worsening through the diary, and recording each event on its own form with onset, treatment, setting and resolution.

The definition must be applied consistently. Severity usually depends on what treatment was given and where, which is why the form should capture those facts as structured fields rather than asking the investigator for a severity label alone. Events that start within a set number of days of a previous one are often counted as the same exacerbation; write that rule into the protocol and apply it in analysis.

Run-in periods

Most respiratory trials start with a run-in of two to four weeks to confirm eligibility, stabilise background therapy, check inhaler technique and establish diary compliance. Running the run-in diary in the same study as the treatment period keeps baseline and outcome on the same data.

Schedule of assessments · 52-week COPD trial
AssessmentScrRun-inBLW4W12W26W52
Spirometry
Daily eDiaryDDDDDD
CAT
Exacerbation review
Adverse events

D = daily diary entries

Daily diary

Rescue medication and symptoms, every day, on their phone

Participants record symptoms, night-time waking and rescue inhaler puffs each evening from a secure link, with no app to install. Completion windows prevent back-filling a week from memory, reminders prompt missed entries, and the dashboard shows participants whose compliance is slipping.

  • Daily recurring diary with a completion window.
  • Reminders that respect quiet hours.
  • Compliance per participant on the dashboard.
Patient diary software
ePRO compliance by site
Site 0194%
Site 0281%
Site 0358%

At-risk participants

03-0073 diary entries missedReminder delivered
03-011Week 4 questionnaire overdueEmail bounced

Visit data

Spirometry, vital signs and safety in the same casebook

Spirometry values are numeric fields with units and range checks that raise an auto-query when a value breaks a rule. Exacerbations, adverse events and concomitant medications such as systemic corticosteroid courses live in the same study, so the events that define the endpoint and the safety data never need reconciling across systems.

  • Range checks with auto-queries.
  • Exacerbation, AE and con med forms together.
  • SDV per field on endpoint data.
Edit checks software
Vital signs · Systolic blood pressure

Edit checks / auto-queries

2
Auto-query

Type

Range High

Operator

Greater than

Value

180

Priority: High

Auto-query

Type

Range Low

Operator

Less than

Value

80

Priority: Normal

Query raised automatically

Value 192 violates limit (180). Please verify.

Build an exacerbation form and a daily diary

Try both in the free sandbox and complete the diary on your phone.

Build your respiratory study free

Endpoints

Common respiratory endpoints and the data behind them

EndpointTypical useData needed
Annualised exacerbation rateCOPD, severe asthmaEvent forms with onset, treatment, setting and resolution; time on study
Trough or peak FEV1Bronchodilators, maintenance therapySpirometry at visits, timing relative to dose
Rescue medication useAsthma and COPDDaily diary of puffs or occasions
CAT or SGRQCOPD health statusQuestionnaires at visits
ACT or ACQAsthma controlQuestionnaires at visits
Oral corticosteroid reductionSevere asthma biologicsCon med doses over time

Phenotypes

Biomarker-defined populations

Modern asthma and COPD drugs often target specific inflammatory pathways, so trials enrol or stratify by biomarkers such as blood eosinophil counts or exhaled nitric oxide. Those values need to be recorded at screening as structured laboratory data with units and collection dates, verified against source, and made available to randomisation as stratification factors where the design requires it.

Because eosinophil counts vary with steroid use and time of day, protocols define when samples are taken and what counts as a qualifying value. Record the details the definition depends on. See clinical trial randomization software for stratified allocation.

Study build

Respiratory study build checklist

Exacerbation definition

Moderate and severe criteria, and the rule for separating events.

Run-in diary

Length, compliance threshold and eligibility checks.

Spirometry standards

Timing relative to dose and central over-reading if used.

Rescue medication

Daily diary fields and units (puffs or occasions).

PRO schedule

CAT, SGRQ, ACT or ACQ matched to recall periods.

Stratification factors

Biomarkers or exacerbation history configured before first randomisation.

FAQ

Questions teams ask before they switch

Something not covered here? Ask us directly.

What is the primary endpoint in COPD trials?

Often the annualised rate of moderate or severe exacerbations, or lung function (FEV1) for bronchodilators.

How are exacerbations defined?

Commonly by treatment and setting: moderate events need systemic corticosteroids or antibiotics, severe events need hospital admission or emergency care. Each protocol defines its own criteria.

Why do respiratory trials last a year?

Exacerbations are seasonal, so a 52-week study covers the full cycle of risk.

Can participants record rescue inhaler use at home?

Yes. A daily diary opens on the participant's phone from a secure link, with windows and reminders.

Do participants need an app?

No. Questionnaires and diaries open in the phone browser.

Can I try it free?

Yes, in the free sandbox with every feature.

Every exacerbation counted

Event forms, daily diaries and PROs in one study. Free sandbox.

Build your respiratory study free